Loading
Latest filing published 11 Aug 2023 for Sigilon Therapeutics, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Josias Pontes discloses dealings in Sigilon Therapeutics, Inc. to SEC (Form 4). In total, 3 filings cover trades dated from 30 September 2021 to 11 August 2023.
The filings describe grants, exercises and other transfers rather than trades on the open market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
Most recently, on 11 August 2023, the filings show a transaction in Sigilon Therapeutics, Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations